SNAPAAV
Dead / Abandoned — Abandoned — no statement of use filed (as of 14 Jul 2025)
What this means for you
This application is over — abandoned 14 Jul 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98313180
- Mark type
- Stylized text
- Filed
- 13 Dec 2023
- Published for opposition
- 29 Oct 2024
- Abandoned
- 14 Jul 2025
- Attorney of record
- Rosaleen H. Chou
Goods and services
- Class 040 — Treatment of materials: Custom manufacturing of pharmaceuticals, biological preparations, chemical preparations, and reagents for others; biomanufacturing for others, namely, manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; biomanufacturing for others, namely, platforms for manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; consulting services in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; custom processing and manufacture of vectors, cells and proteins for use in the field of biotechnology
- Class 042 — Scientific and technological services: Research, development, and consulting services related thereto in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; genetic engineering services, namely, research in the field of genetics; biotechnology research and development; scientific, pharmaceutical, and medical research services in the field of biological treatment and bioproduction; design and development of biotechnology platforms relating to biological treatment for use in the manufacture of pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; providing scientific research information, namely, provision of information for research and development of biopharmaceuticals that are manufactured using biological treatment and bioproduction platforms; development of new technology for others in the field of biotechnology, biomanufacturing, and pharmaceuticals; new product design services; biotechnology design services, namely, the creation of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins
Owner
- National Resilience, Inc., San Diego, CA, US
- National Resilience, Inc., San Diego, CA, US
Prosecution history
- 14 Jul 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 14 Jul 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 10 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Oct 2024 — PUBLISHED FOR OPPOSITION
- 09 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Aug 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 30 Aug 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 16 Jul 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 16 Jul 2024 — NON-FINAL ACTION E-MAILED
- 16 Jul 2024 — NON-FINAL ACTION WRITTEN
- 12 Jul 2024 — ASSIGNED TO EXAMINER
- 13 Mar 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED